López-Íńiguez A

Language: Spanish
References: 20
Page: 62-68
PDF size: 565.43 Kb.

ABSTRACT

The endocrinous tumors of adrenal tissue, pheochromocytoma and paraganglyoma have an incidence of 2 to 8 cases per million annually. Clinical manifestations will depend on the cathecolamine secretion, being refractory hypertension the most frequent, which will subside completely if the tumor is removed. They can be originated either from genetic diseases or from de novo mutations. Genetic diseases that are associated with these kinds of tumors are; Multiple Endocrine Neoplasia type 2, Neurofibromatosis type 1 (NIF 1), Von Hippel-Lindau disease and hereditary paraganglyoma. Diagnosing these neoplasia can be complex in spite of presenting characteristic clinical manifestations and specific biological and radiological markers. Pheochromocytoma and hereditary paraganglyoma should always be a differential diagnosis when evaluating hypertension.

REFERENCES

1. Hartmut P.H., Neumann M.D, Vortmeyer Alexander et al. Evidence of MEN-2 in the original Description of Classic Pheochromocytoma. N Eng J Med 2007; 357; 1311-5.

2. Klein R., Lloyd R., Young W. Hereditary Paraganglioma-Pheochromocytoma Syndromes. Gene Reviews University of Washington, Seattle. 2009

3. Amna Khan. Composite Pheochromocytoma-Ganglioneuroma: A rare experiment of Nature. Endocrine Practice 2010; 16 No. 2 March/April.

4. Dluhy R. Pheochromocytoma Death of an Anxiom. N Eng J Med 2002; 346: No. 19

5. Pacak K., Graeme E., Ilias I. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones Int J Endocr Met. 2009 8(2); 111-116.

6. Zografos G., Vasiliadis G., Zagoun F. et al. Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. W J Surg Onco 2010; 8:14.

7. Isobe K., Fu L., Tatsuno H. et al. Adiponectin and Adiponectin receptors in Human Pheochromocytoma. J Atheroscler Thromb 2009; 16: 442-447, No. 4.

8. Young W.F. The Incidentally Discovered Adrenal Mass. N Eng J Med 2007; 356;6.

9. Lee J.W., Kim J.Y., Youn Y.J. et al. Clinical Characteristics and Prognostic Factors of Stress-Induced Cardiomyopathy. Korean Circ J. 2010; 40: 6-277.

10. Ziegler C.G., Brown J.W., Schally A.V. et al. Proc Natl Acad Sci USA 2009; 106; 37. 15879-15884.

11. Procopiou M., Finney H., Akker S.A., et al. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J Endocr 2009 161; 131-140.

12. Barron J. Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis. J Clin Path 2010; 63: 669-674.

13. Hoefnagel C.A. Radionuclide Therapy revisited. Eur J Nucl Med 2002; 18:408-31.

14. Motta-Ramirez G.A., Remer E.M., Herts B.R. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. Am J Roentgenol. 2005; 185:684-8.

15. Havekes B., King K., Lai E.W., et al. New Imaging approaches to Pheochromocytoma and paraganglioma. Clin Endocr 2010; 72: 137-145.

16. Santarpia L., Habra M.A., Jiménez C. Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies. Horm Metab Res. 2009; 41: 680-686.

17. Agarwal A., Mehrotra P. et al. Size of the Tumor and Pheochromocytoma of the Adrenal Gland Scaled Score (PASS): Can They Predict Malignancy?. W J Surg 10.1007/s00268-010-0744-5.

18. Eisenhauer E.A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline. Eur J Ca 2009; 45: 228-247.

19. Arias-Martínez N., Barbado-Hernández F.J., Couto-Caro R. et al. Treatment of Malignant Pheochromocytoma with I-MIBG: A long Survival. An Med Interna 2003; Vol 20 No 11; 575-578.

20. Adjalle R., Plouin P.F., Pacak K., Lehnert H. Treatment of Malignant Pheochromocytoma. Horm Metab Res. 2009; 41: 687-696.